Higher levels of CD4-positive naïve T cells in patients receiving CAR T-cell therapy for multiple myeloma are associated with ...
While chimeric antigen receptor (CAR) T cell therapy is an essential therapeutic option for prolonging survival in patients with relapsed or refractory non-Hodgkin lymphomas (NHL), profound immune ...
Patients treated in an outpatient setting who later required admission spent an average of 12.1 days in the hospital, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback